GlassScriptPhysician profile
Paul A Melnick
NPI 1295792661
$12,194.75
in general payments reported to CMS, 2019-2025
34 companies · $930 in 2025
The $930 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,839 · 2020: $492 · 2021: $1,955 · 2022: $1,360 · 2023: $1,421 · 2024: $1,198 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,124 · Consulting Fee: $300 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,123.60 |
| Consulting Fee | $300.00 |
| Education | $124.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $3,703.51 | 2019-2023 | Firdapse |
| Biogen, INC. | $2,153.46 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $1,155.43 | 2019-2025 | |
| Banner Life Sciences, LLC | $940.22 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $931.66 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Genzyme Corporation | $425.39 | 2019-2021 | |
| Abbvie INC. | $409.94 | 2019-2025 | |
| Lilly USA, LLC | $276.67 | 2020-2025 | Emgality, Reyvow, Amyvid |
| Ucb, INC. | $244.18 | 2023-2025 | Rystiggo |
| Emd Serono, INC. | $221.22 | 2019-2024 | Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $205.51 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $184.74 | 2019-2022 | |
| Neurelis, INC. | $142.35 | 2023-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $119.91 | 2019-2024 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $119.67 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $108.91 | 2022-2024 | |
| Celgene Corporation | $108.27 | 2020-2025 | Zeposia |
| Argenx US, INC. | $102.73 | 2022-2023 | Vyvgart, Vyvgart Hytrulo |
| Tanabe Pharma America, INC. | $91.35 | 2021-2024 | |
| Alnylam Pharmaceuticals INC. | $75.01 | 2019-2025 | |
| Kyowa Kirin, INC. | $71.71 | 2024 | Nourianz |
| Pfizer INC. | $67.10 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $48.68 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $48.56 | 2024-2025 | Ponvory |
| Amgen INC. | $45.48 | 2019-2024 | Uplizna |
| Genentech USA, INC. | $39.12 | 2024 | Ocrevus, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $27.59 | 2023-2025 | |
| Acorda Therapeutics, INC | $26.90 | 2019-2023 | Inbrija, Ampyra |
| Xeris Pharmaceuticals, INC. | $23.56 | 2022 | |
| Sk Life Science, INC. | $23.00 | 2024 | |
| Arbor Pharmaceuticals, INC. | $14.17 | 2021 | |
| Portola Pharmaceuticals, LLC | $13.94 | 2019 | |
| Avion Pharmaceuticals | $13.24 | 2022 | |
| Adamas Pharmaceuticals, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Melnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.